<DOC>
	<DOC>NCT02864407</DOC>
	<brief_summary>To monitor the safety profile and effectiveness of Vahelva Respimat in Korean patients with COPD in a routine clinical practice setting</brief_summary>
	<brief_title>Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>Study Design: regulatory PMS study</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criteria: Patients who have been started on Vahelva Respimat in accordance with the approved label in Korea Age &gt;= 18 years at enrolment Patients who have signed on the data release consent form Exclusion criteria: Patients with hypersensitivity to Vahelva Respimat or to any of the excipients. Patients with a history of hypersensitivity to atropine or its derivatives(e.g. ipratropium, oxitropium, glycopyrronium, clidinium, umeclidinium) Patients with asthma Current participation in other clinical trials</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>